At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses results from ASCEND-1 and ASCEND-2, two non-randomized phase 1/2 multicenter, open-label, single-arm trials evaluating the efficacy of ceritinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, in patients with pretreated, ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.